RETRACTED: Protective Effect of Hibifolin on Lipopolysaccharide‐Induced Acute Lung Injury Through Akt Phosphorylation and NFκB Pathway
Environmental Toxicology · 2025
DOI: 10.1002/tox.24383 ↗Kurz gefasst
Zurückgezogene Publikation in der Zeitschrift Environmental Toxicology, 2025. Verfasst von Yan-Yan Ng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric, Chung Kang Branch, Cheng Ching Hospital, Taichung, Taiwan. Hauptthemen laut MEDLINE: Acute Lung Injury, Proto-Oncogene Proteins c-akt, NF-kappa B, Anti-Inflammatory Agents. Die Arbeit nennt 28 Literaturangaben. Gefördert von: Chung-Kang Branch of the Cheng Ching General Hospital Research Fund, Chung Shan Medical University Hospital, National Science and Technology Council of Taiwan.
Abstract (Originalsprache)
Acute lung injury (ALI) is a difficult condition to manage, especially when it is complicated by bacterial sepsis. Hibifolin, a flavonoid glycoside, has anti‐inflammatory properties that make it a potential treatment for ALI. However, more research is needed to determine its effectiveness in LPS‐induced ALI. In this study, male ICR mice were treated with hibifolin before LPS‐induced ALI. Protein content and neutrophil count in bronchoalveolar lavage (BAL) fluid were measured by BCA assay and Giemsa staining method, respectively. The levels of proinflammatory cytokines and adhesive molecules were detected by ELISA assay. The expression of NFκB p65 phosphorylation, IκB degradation, and Akt phosphorylation was assessed by western blot assay. Hibifolin pre‐treatment significantly reduced pulmonary vascular barrier dysfunction and neutrophil infiltration into the BAL fluid in LPS‐induced ALI mice. In addition, LPS‐induced expression of proinflammatory cytokines (IL‐1β, IL‐6, TNF‐α) and adhesive molecules (ICAM‐1, VCAM‐1) within the BAL fluid were markedly reduced by hibifolin in LPS‐induced ALI mice. More, hibifolin inhibited LPS‐induced phosphorylation of NFκB p65, degradation of IκB, and phosphorylation of Akt in lungs with ALI mice. In conclusion, hibifolin shows promise in improving the pathophysiological features and proinflammatory responses of LPS‐induced ALI in mice through the NFκB pathway and its upstream factor, Akt phosphorylation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric, Chung Kang Branch, Cheng Ching Hospital, Taichung, Taiwan.
- Center for General Education, Chung Shan Medical University, Taichung, Taiwan.
- School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
- Department of Family and Community Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan.
- School of Public Health, Chung Shan Medical University, Taichung, Taiwan.
- Department of Dermatology, The First Affiliated Hospital of Jinan University, Guangzhou, China.
ORCID-Profile: Yu-Hsiang Kuan
Förderung
- Chung-Kang Branch of the Cheng Ching General Hospital Research Fund
- Chung Shan Medical University Hospital
- National Science and Technology Council of Taiwan
- National Science and Technology Council
Zitieren
APA
Ng, Y. Y., Ho, Y. C., Yen, C. H., Lee, S. S., Tseng, C. C., Wu, S. W., & Kuan, Y. H. (2025). RETRACTED: Protective Effect of Hibifolin on Lipopolysaccharide‐Induced Acute Lung Injury Through Akt Phosphorylation and NFκB Pathway. Environmental Toxicology. https://doi.org/10.1002/tox.24383
Vancouver
Ng YY, Ho YC, Yen CH, Lee SS, Tseng CC, Wu SW, et al. RETRACTED: Protective Effect of Hibifolin on Lipopolysaccharide‐Induced Acute Lung Injury Through Akt Phosphorylation and NFκB Pathway. Environmental Toxicology. 2025. doi:10.1002/tox.24383
BibTeX
@article{Ng2025,
author = {Ng, Yan-Yan and Ho, Yung-Chuan and Yen, Chi-Hua and Lee, Shiuan-Shinn and Tseng, Ching-Chi and Wu, Sheng-Wen and Kuan, Yu-Hsiang},
title = {RETRACTED: Protective Effect of Hibifolin on Lipopolysaccharide‐Induced Acute Lung Injury Through Akt Phosphorylation and NFκB Pathway},
journal = {Environmental Toxicology},
year = {2025},
doi = {10.1002/tox.24383}
}
EUVIMED